P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)
| Autor: | Haakensen, V., Nowak, A., Ellingsen, E., Grundberg, O., Farooqi, S., Mcculloch, T., Cedres, S., Bjaanæs, M., Helland, Å. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology March 2021 16(3) Supplement:S380-S380 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|